BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clinical Study Demonstrates That ONCURA's RAPID Strand(TM) Offers Improved Delivery Of Therapy For Patients Choosing Brachytherapy To Treat Prostate Cancer


10/19/2005 5:12:25 PM

PHILADELPHIA, Dec. 9 /PRNewswire/ -- As a global leader in minimally invasive prostate cancer treatment ONCURA(TM) encourages the publication of data that demonstrates improvements in the clinical application of prostate brachytherapy. A recent publication in the journal Brachytherapy reports on the use of ONCURA's RAPID Strand, and compares its delivery of therapy with that delivered to a group of patients treated with loose seeds.

"The use of RAPID Strand has lead to a significant improvement in the effective delivery of planned treatment for prostate cancer," said the lead author, Humberto Fagundes, M.D., a Radiation Oncologist at Missouri Baptist Medical Center. He added, "In addition the incidence of certain urinary side effects, such as retention, showed a significant decrease in the RAPID Strand patients."

This study on 473 patients focused on the measurement of radiation dose delivered to the prostate and the surrounding anatomy as this is a documented method of assessing the likelihood of the long-term success of brachytherapy, as well as the chance of certain side effects. RAPID Strand clearly demonstrated a significant improvement in these measurements, although longer term follow-up is needed to determine the exact clinical benefits.

"Dr Fagundes has achieved excellent results using a novel technique, originally described by Dr. Batterman from Utrecht in The Netherlands, in which RAPID Strand is after-loaded into the prostate through previously inserted needles," said Andrew Bright, ONCURA's Vice President of Strategic Marketing. He added, "The technique allowed the use of RAPID Strand in what is often referred to as a 'real-time' approach to prostate brachytherapy and may encourage other physicians who favor this approach to adopt RAPID Strand."

ONCURA was created through the merger of Amersham plc's brachytherapy business and Galil Medical Ltd.'s urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA's International business is operated from its UK subsidiary. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.

ONCURA

CONTACT: Andrew Bright, ONCURA, +1-484-530-3922,andrew.bright@oncura.com



Read at BioSpace.com

ONCURA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES